LM49

LM49 is a synthetic small molecule derivative of licochalcone A, a natural chalconoid found in licorice (*Glycyrrhiza* species). Developed by researchers at the Shanxi University of Traditional Chinese Medicine, LM49 is being investigated as a potential therapeutic agent for diabetic nephropathy (DN). Its primary mechanism of action involves the inhibition of the Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling pathway, which plays a crucial role in mediating the inflammatory response and oxidative stress in renal tissues under high-glucose conditions. Furthermore, LM49 has been shown to suppress the TGF-β1/Smad signaling pathway, thereby inhibiting the activation of renal mesangial cells and the subsequent accumulation of extracellular matrix proteins, which are hallmarks of renal fibrosis. Preclinical studies in animal models of diabetes have demonstrated that LM49 can improve renal function, reduce proteinuria, and attenuate pathological changes such as glomerular hypertrophy and basement membrane thickening.